Compare AR & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AR | ELAN |
|---|---|---|
| Founded | 2002 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 11.8B |
| IPO Year | 2013 | 2018 |
| Metric | AR | ELAN |
|---|---|---|
| Price | $33.69 | $24.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 10 |
| Target Price | ★ $47.13 | $27.89 |
| AVG Volume (30 Days) | 4.4M | ★ 5.2M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1027.78 | N/A |
| EPS | ★ 1.72 | 0.11 |
| Revenue | ★ $5,275,823,000.00 | $4,715,000,000.00 |
| Revenue This Year | $29.74 | $8.21 |
| Revenue Next Year | $5.07 | $5.31 |
| P/E Ratio | ★ $19.72 | $220.32 |
| Revenue Growth | ★ 21.97 | 6.22 |
| 52 Week Low | $29.10 | $13.16 |
| 52 Week High | $45.75 | $27.72 |
| Indicator | AR | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 37.47 | 54.91 |
| Support Level | $32.86 | $23.72 |
| Resistance Level | $35.68 | $25.85 |
| Average True Range (ATR) | 1.01 | 1.00 |
| MACD | -0.17 | 0.06 |
| Stochastic Oscillator | 7.71 | 38.90 |
Antero Resources is an exploration and production firm whose operations represent a pure play in the Marcellus Shale, located in northern West Virginia. The company started in 2002 as an E&P focused on the Barnett Shale (Fort Worth, Texas). Antero redefined itself in Appalachia's Marcellus Shale in 2005. In 2012, shortly before Antero's 2013 IPO, Antero Midstream Partners was formed to handle the company's rapidly growing gas volumes. In 2026, the firm narrowed its focus further by selling its Ohio Utica assets and using the proceeds to acquire additional Marcellus acreage from HG Energy. Just over half of its production and earning power is tied to natural gas, with the remainder mostly NGLs, where it holds a leading position, and some crude oil.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.